JSC
RARE icon

Jackson Square Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

Jackson Square Capital’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-100
Closed -$4K – 395
2019
Q4 		$4K Buy
+100
New +$4.13K ﹤0.01% 338

Other funds holding RARE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Jackson Square Capital's RARE Position: Q1 2020 in Review

Jackson Square Capital sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2020, closing a stake of 100 shares — an estimated $4K sold.

Jackson Square Capital first reported a position in RARE in Q4 2019 and held it in 1 quarter. The position peaked at $4K in Q4 2019. 174 funds tracked by Wall St. Rank hold RARE as of Q1 2020.

  • Jackson Square Capital reported no remaining Ultragenyx Pharmaceutical position as of Q1 2020 after selling out during the quarter.
  • Jackson Square Capital sold 100 Ultragenyx Pharmaceutical shares in Q1 2020, an estimated $4K.
  • Jackson Square Capital first reported a position in Ultragenyx Pharmaceutical in Q4 2019 and held it in 1 quarter.
  • Jackson Square Capital's Ultragenyx Pharmaceutical position peaked at $4K in Q4 2019.
  • 174 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2020.

Based on Jackson Square Capital's 13F filing for Q1 2020, filed 15 May 2020.